



**COMPETITIVE TECHNOLOGIES**  
 Unlocking the Potential of Innovation®  
 Technology Transfer & Licensing Services

**NYSE Alternext US: CTT** 10/28/08  
 Share Price: \$ 1.34  
 Price Range (52 weeks) \$ 1.05 – 3.42  
 Approx. Shares Outstanding: 8.3 million  
 Website: [www.competitivetech.net](http://www.competitivetech.net)

## FACT SHEET

- **Corporate Overview** Competitive Technologies, Inc., based in Fairfield, CT, is a global leader in identifying, developing, and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT provides distribution, patent and technology transfer, selling and licensing services. It focuses on customer needs and matching those needs with commercially viable technology or product solutions provided by its clients.
- **Market** CTT is well positioned to capitalize on factors driving the growth of the innovative product distribution and technology licensing market: the increasing number of new patents, the fast-moving technology market cycle, high cost of R&D, and scarcity of R&D talent. US patent applications have grown to a record-breaking 465,000+ in fiscal 2007 from approximately 100,000 in fiscal 1980.
- **Strategy** CTT obtains customers' requirements, their wish lists, and leverages its inventory of exclusive products and technologies and its extensive sourcing network to identify and commercialize products and technologies that fulfill unsatisfied needs.

## EXECUTIVE MANAGEMENT TEAM

John B. Nano, Chairman, President and CEO  
 Aris D. Despo, Executive V.P., Business Development  
 Girish Nallur, Executive V.P. and CSO  
 John Rafferty, Vice President and Controller

- **Revenue** CTT earns revenue in two ways, from licensing our clients' and our own technologies to licensees, and in a business model that allows us to share in the profits of distribution of finished products. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. CTT has successfully licensed more than 500 technologies to over 400 individual organizations.
- **Clients and Customers** CTT's activities are global, with recent strong growth in Asia and Europe. CTT's primary focus is directed at developing relationships with customers who have technology or product requirements. CTT continues to nurture and develop relationships with its historical sources, including universities, corporations, independent research institutions and individuals.

CTT is a vital part of the technology commercialization community, and has paid over \$100 million to universities in shared technology revenues.

## FINANCIALS (\$000) (Fiscal Year Ends July 31)

	<u>FY2008</u>	<u>FY2007</u>	<u>FY2006</u>	<u>FY2005</u>	<u>FY2004</u>
Revenues	\$ 1,194	\$ 4,167	\$ 5,188	\$ 14,174	\$ 8,022
Expenses and Taxes	7,160	13,061	7,565	8,472	5,067
Net Income/(Loss)	(5,966)	(8,894)	(2,377)	5,702	2,955
Net Income/(Loss) \$/per share *	\$ (0.73)	\$ (1.11)	\$ (0.31)	\$ 0.78	\$ 0.46
Shares Outstanding (000) *	8,156	8,040	7,652	7,325	6,457
	<u>July 31, 2008</u>	<u>July 31, 2007</u>	<u>July 31, 2006</u>	<u>July 31, 2005</u>	<u>July 31, 2004</u>
Cash/Cash Equiv./Restricted Cash	\$ 2,237	\$ 6,572	\$ 12,909	\$ 14,280	\$ 4,310
Other Current Assets	438	2,792	4,576	4,358	1,039
Other Assets	436	349	932	803	1,332
Current/Non-Current Liabilities	1,517	2,114	3,963	5,333	1,742
Shareholders' Equity	1,594	7,599	14,454	14,108	4,939

\* diluted when applicable

This information should not be construed as an offer to sell or solicitation of an offer to buy Competitive Technologies securities. Statements about our future expectations, are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

(over)

**DIRECT INQUIRIES TO:**

Johnnie D. Johnson, IR Services, LLC, Tel: (860) 434 2465  
jdjohnson@corpirservices.com, [www.competitivetech.net](http://www.competitivetech.net)

- *Technologies* – CTT's portfolio of commercially viable products and technologies exploits the opportunities of the paradigm shift resulting from record high costs of both healthcare and energy, with potential to provide solutions in rapidly growing markets:

*Pain Management Therapy:* CTT has worldwide exclusive rights to a non-invasive pain management therapy device for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the technology was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community™. The multiprocessor apparatus is designed to simultaneously treat multiple pain areas by means of single-use surface electrodes applied to the skin area corresponding to the pain. With Medical Device CE certification and permission to be sold throughout Europe, it has successfully been used to treat over 2,300 patients in European hospitals. CTT licensee GEOMC of Korea is manufacturing the device commercially for worldwide sales. Country-exclusive distribution agreements have been signed for India, Korea and Bangladesh. US patent and FDA 510(k) medical device authorization approvals are pending. CTT is currently in the process of reviewing and selecting distributors from a targeted list of companies representing the U.S. and global markets in Europe, Asia and Latin America.

*Nanotechnology Bone Biomaterial:* CTT has exclusive rights to the patented nanoparticle-formulated biomaterial for skeletal bone repair. The flowable, moldable paste forms a solid bone-like structure capable of stabilizing fractured bone within 15 minutes. The technology has superior compressive strength, is machinable and drillable. It can be used for human bones and for dental and veterinary uses. Soteira, Inc. was granted an exclusive license for applications related to the human spine.

*Sexual Dysfunction Therapeutic:* CTT has exclusive rights to license for development a sexual dysfunction therapeutic. The therapeutic acts on brain receptors to stimulate natural sexual arousal without acting directly on the vascular system, and is effective on both males and females.

*Solar Power:* CTT has exclusive worldwide rights to the group of patents related to methods of adapting organic light emitting diodes (OLED) technology for solar power. The technology uses a bulk heterojunction structure creating solar power using OLED donor/acceptor nanoparticles in a patented charge carrier matrix. The photovoltaic (PV) technology uses bilayer particles in the matrix to cost-efficiently produce electric current from light.

*Compressed Air Drying Device:* CTT has exclusive North American rights to a patented air-purifying device from SECO Engineering S.r.l. The device eliminates water condensation, oil residues, and solid particles that are contaminants present in compressed air lines, extending the life of pneumatic tools. Applications include aerospace, air-actuated doors, control valves, pneumatic tools, mining and excavation equipment, and processing and packaging machines.

*MC Square Device:* CTT has exclusive US rights to the MC Square device for stress management and memory improvement. The pocket-sized device, convenient and easy-to-use, targeting markets from students to the aging population, uses synchronized sound and light rhythms to influence brain activity. Over 1.2 million units have been sold in Korea. The technology was developed by CTT's clients, GEOMC of Korea and Thomas Jefferson University in Philadelphia.

*Breast Cancer Test:* CTT has rights to the patented breast cancer detection device, Early Breastest™, from the research of Milton Schonberger and Dr. Anthony Barbara. The non-invasive technology generates an analysis that detects angiogenesis, using adhesive pads embedded with hundreds of thermistors, micro-thermometers. The Schonberger patent for the world's first disposable thermometer is the basis for this new technology.

*Unitary Anastomotic Device:* CTT has exclusive US rights to a patented UAD prosthetic device for vascular and visceral surgical procedures invented in Brazil. With no required suturing or clamping, post-operative complications, and surgical and recovery time are greatly reduced. Used in coronary bypass, treatment of peripheral artery disease and organ transplants.

*Skin Pigment Enhancer:* Clinuvel Pharmaceuticals Ltd. (AUS: CUV) is the exclusive sub-licensee for this sunless-tanning technology being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis. CTT will receive royalties on sales of products using its technology. Orphan Drug Designation has been granted by US FDA.

*Lupus Diagnostic and Monitoring Technology:* CTT has exclusive worldwide rights to the patented laboratory test developed at the Lahey Clinic to diagnose and monitor Systemic Lupus Erythematosus. This cost-effective, scalable testing platform for early detection of Lupus, which affects approximately 1.5 million patients in the U.S., monitors therapeutic efficacy and flares.

*Encryption Technology:* Public key encryption technology that operates at high speeds with low processing and memory requirements. Secure applications include the Internet, telecommunications, smart-cards and e-commerce.

*Video & Audio Signal Processing – Encoding & Compression:* CTT owns rights to two compression technologies in the MPEG LA-administered MPEG-4 Visual Patent Portfolio License Pool, which has over 500 licensees. Applications include wireless video conferencing, wired videophones, remote security cameras, medical imaging, and pilot info systems/displays.